Structural Changes of the Substantia Nigra in Parkinson's Disease as Revealed by MR Imaging

References

1. ↵
   Duvoisin RC. Familial Parkinson's disease. Neurosci News 1998;1:43-46
2. ↵
   Barkats M, Bilang-Bleuel A, Buc-Caron MH, et al. Adenovirus in the brain: recent advances in gene therapy for neurodegenerative diseases. Prog Neurobiol 1998;55:333-341

   CrossRefPubMedWeb of Science
3. Freese A. Restorative gene therapy approaches to Parkinson's disease. Med Clin North Am 1999;83:537-548

   CrossRefPubMed
4. ↵
   Fahn S, Elton ER. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Press; 1987:293-304
5. ↵
   Brooks DJ. Motor disturbance and brain functional imaging in Parkinson's disease. Eur Neurol 1997;38[suppl]:26-32

   CrossRefPubMedWeb of Science
6. Shinotoh H, Calne DB. The use of PET in Parkinson's disease. Brain Cogn 1995;28:297-301

   CrossRefPubMed
7. Sawle GV, Playford ED, Burn DJ, Cunningham VJ, Brooks DJ. Separating Parkinson's disease from normality: discriminant function analysis of fluorodopa F 18 positron emission tomography data. Arch Neurol 1994;51:237-243

   CrossRefPubMedWeb of Science
8. Sawle GV. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography? Mov Disord 1993;8:271-277

   CrossRefPubMed
9. ↵
   Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998;39:1500-1508

   Abstract/FREE Full Text
10. Seibyl JP, Marek KL, Quinlan D, et al. Decreased SPECT beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598

    CrossRefPubMedWeb of Science
11. Vermeulen RJ, Wolters EC, Tissingh G, et al. Evaluation of beta-CIT with SPECT in controls, early and late Parkinson's disease. Nucl Med Biol 1995;22:985-991

    CrossRefPubMed
12. ↵
    Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995;45:1138-1143 [published erratum appears in Neurology1995 ;45>:1420]

    Abstract/FREE Full Text
13. Ordidge RJ, Gorell JM, Deniau JC, Knight RA, Helpern JA. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 tesla. Magn Reson Med 1994;32:335-341

    CrossRefPubMedWeb of Science
14. ↵
    Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M. T2 relaxation time in patients with Parkinson disease. Neurology 1993;43:697-700

    Abstract/FREE Full Text
15. ↵
    Moriwaka F, Tashiro K, Itoh K, Hamada T, Miyasaka K. Magnetic resonance imaging in Parkinson's disease: the evaluation of the width of pars compacta on T2 weighted images [in Japanese]. Rinsho Shinkeigaku 1992;32:8-12

    PubMed
16. Mauricio JC, Coelho H, Sa J, Martins A. Importance of magnetic resonance in Parkinson disease: an analytic study of the pars compacta. Acta Med Port 1990;3:85-88

    PubMed
17. Duguid JR, De La Paz R, DeGroot J. Magnetic resonance imaging of the midbrain in Parkinson's disease. Ann Neurol 1986;20:744-747

    CrossRefPubMedWeb of Science
18. ↵
    Fearnley JM, Lees AJ. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301

    CrossRefPubMedWeb of Science
19. ↵
    Brooks DJ. The early diagnosis of Parkinson's disease. Ann Neurol 1998;44[suppl 1]:S10-S18

    CrossRefPubMedWeb of Science